Skip to content
Med Pharma News

Med Pharma News

Your Daily Dose of Pharma News

  • About Med Pharma News
  • Contact Us
  • News
  • Privacy Policy
  • Terms and Conditions
  • Home
  • Industry Insights
  • Page 4

Category: Industry Insights

Get the latest industry insights and trends in the pharmaceutical sector with Med Pharma News. Stay informed about groundbreaking research, regulatory updates, and market analysis.

Bristol Myers Squibb Q3 2026 results graphic about growth versus legacy portfolio
  • Industry Insights

Bristol Myers Squibb Q3 2026 Results: Growth Portfolio Now 59% of Sales as Eliquis Cliff Nears

Megan Wood3 weeks ago010 mins

The Bristol Myers Squibb Q3 2026 results lift revenue guidance as the Growth Portfolio hits 59% of sales. The Eliquis cliff explained.

Read More
Fortis Healthcare acquisition graphic about price and strategy
  • Industry Insights

Fortis Healthcare Acquisition: What ₹277 Crore for Suguna Hospital Says About Bengaluru Cluster Strategy

Megan Wood3 weeks ago010 mins

The Fortis Healthcare acquisition of Suguna Hospital: price per bed, the cluster strategy and the profit data not yet disclosed.

Read More
Laurus Labs Q2 results graphic about CDMO mix and margins
  • Industry Insights

Laurus Labs Q2 Results: How CDMO Mix Drove a 126% Jump in Net Profit

Megan Wood3 weeks ago010 mins

The Laurus Labs Q2 results show strong operating leverage from CDMO mix. Segment split, margin bridge and what is undisclosed.

Read More
Eli Lilly Q3 2026 results graphic about price, volume and guidance
  • Industry Insights

Eli Lilly Q3 2026 Results: Price, Volume and the Guidance Split Explained

Megan Wood3 weeks ago3 weeks ago010 mins

A financial reading of the Eli Lilly Q3 2026 results: price versus volume, one-time items, the EPS cut and what guidance implies for Q4.

Read More
Molecular Partners workforce reduction 2026 graphic about cash and strategy
  • Industry Insights

Molecular Partners Workforce Reduction 2026: What the 44% Cut Means for Cash and Strategy

Megan Wood3 weeks ago011 mins

What the Molecular Partners workforce reduction 2026 means for cash, costs and the radiotherapy pipeline, and what is still unreported.

Read More
Geron IMpactMF trial discontinued graphic about business impact
  • Industry Insights

Geron IMpactMF Trial Discontinued: What It Means for the Company and the Sector

Megan Wood3 weeks ago011 mins

What the Geron IMpactMF trial discontinued means for strategy, Rytelo and the Q3 results due on 4 November 2026.

Read More
Nucelion Pandorum partnership graphic about the India CDMO sector
  • Industry Insights

Nucelion Pandorum Partnership: What the CDMO Deal Means for India’s Advanced Therapies

Megan Wood3 weeks ago011 mins

What the Nucelion Pandorum partnership means for India’s CDMO sector, PRIP-backed research and investigational eye therapies.

Read More
India cancer medicine price revision 2026 graphic on industry margins
  • Industry Insights

India Cancer Medicine Price Revision 2026: What It Means for Drugmakers and Distributors

Megan Wood3 weeks ago3 weeks ago011 mins

What the India cancer medicine price revision 2026 means for drugmakers, distributors and hospitals, with examples, criticisms and open questions.

Read More
Indira IVF Sabine acquisition investor briefing graphic with growth bars
  • Industry Insights

Indira IVF Sabine Acquisition: What the Reported Deal Means for Investors

Megan Wood3 weeks ago010 mins

What the Indira IVF Sabine acquisition could mean for investors: reported terms, implied valuation, IPO context and what remains undisclosed.

Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 40

Categories

  • Healthcare IT (26)
  • Industry Insights (355)
  • Lifestyle and Wellness (24)
  • Medical Devices (45)
  • Pharmaceuticals (105)
  • Uncategorized (1)

Recent Posts

  • Teva Price-Fixing Settlement: 45 States Strike Deal in Generic Drug Collusion Case
  • Gedeon Richter Mayne Pharma Deal: A$604M Buys a US Women’s Health Platform
  • Lilly Stipple Bio Deal: Why Eli Lilly Is Betting Up to $5.9B on Tumor-Only Targets
  • Lilly Calytrix Acquisition: $1.5B Bet on a Blood Cancer Mutation
  • J&J Ollin Acquisition: $2.2B Bet on an Eye Drug Built to Beat Vabysmo
Digital Newspaper - Multipurpose News WordPress Theme 2026. Powered By BlazeThemes.